THANK YOU FOR SUBSCRIBING
The compay’s initial focus is on addressing the market for beef cattle and dairy in New Zealand, Australia, and California, which is expected to exceed $10 billion by 2030, as per agricultural industry sources.
FREMONT, CA: CH4 Global, a San Francisco, CA-based aquaculture startup, raised a $3m seed funding round.
Investors included family offices and private investors from around the world and government innovation groups, including the New Zealand Provisional Growth Fund, the Australian Fisheries Research Development Corporation, South Australian Research & Development Institute, and the South Australian Landing Pad.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Established 18 months ago by an international team of senior scientists, proven technology entrepreneurs, and business executives from New Zealand, Australia, and the US, CH4 Global is scaling the aquaculture and processing of a specific species of red seaweed – Asparagopsisarmata – as a livestock supplement solution to reduce ruminant methane emissions by up to 90 percent.
The company’s initial focus is on addressing the market for beef cattle and dairy in New Zealand, Australia, and California, which is expected to exceed $10 billion by 2030, as per agricultural industry sources.
CH4 Global’s board and their executive positions are:
Steve Meller, President & CEO
Nick Gerritsen, COO
Guy Royal, Chief Legal Counsel
Larry Howell, Chairman of the Board
“The sad, undeniable truth is we are rapidly running out of time to delay an impending climate crisis,” stated Dr. Steve Meller, President, CEO and Co-Founder of CH4 Global. “Asparagopsisarmata is an Australian- and New Zealand-native, naturally abundant seaweed that can immediately impact climate change. This cold-water seaweed is perfectly suited to the Australian and New Zealand climate for sustainable, long-term, environmentally friendly cultivation. And CH4 Global is well positioned to make it available globally now, not 10 years from now.”
More in News